Omeros (OMER) Capital Expenditures (2010 - 2026)
Omeros (OMER) posted Capital Expenditures of $11000.0 for Q3 2025, down 15.38% sequentially from $13000.0 in Q2 2025, and up 1000.0% YoY from $1000.0 in Q3 2024.
Analysis
Omeros (OMER) Capital Expenditures (2010 - 2026) Analysis & Trends
Omeros has reported Capital Expenditures for 16 years, with the latest figure at $11000.0 in Q3 2025.
- Quarterly Capital Expenditures rose 1000.0% year-over-year to $11000.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $24000.0 (down 83.78% YoY) and the FY2025 annual result came in at $65000.0, down 60.61% from the prior year.
- Capital Expenditures declined to $11000.0 in Q3 2025 per OMER's latest filing, from $13000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $275000.0 in Q2 2023 and troughed at -$3000.0 in Q3 2022.
- A 5-year average of $58937.5 and a median of $37000.0 in 2023 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures plunged 102.91% in 2022, then surged 1200.0% in 2023.
- Over 5 years, Capital Expenditures stood at $74000.0 in 2021, then plunged by 82.43% to $13000.0 in 2022, then soared by 807.69% to $118000.0 in 2023, then plunged by 77.97% to $26000.0 in 2024, then tumbled by 57.69% to $11000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $11000.0, $13000.0, and $41000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | 45,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 45,000.00 |
| Sep 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Mar 31, 2025 | 41,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Mar 31, 2024 | 58,000.00 |
| Dec 31, 2023 | 118,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Jun 30, 2023 | 275,000.00 |
| Dec 31, 2022 | 13,000.00 |
| Sep 30, 2022 | -3,000.00 |
| Dec 31, 2021 | 74,000.00 |
| Sep 30, 2021 | 103,000.00 |
| Jun 30, 2021 | 88,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Sep 30, 2020 | 73,000.00 |
| Jun 30, 2020 | 144,000.00 |
| Mar 31, 2020 | 66,000.00 |